公开(公告)号：US11649506B2

公开(公告)日：2023-05-16

申请号：US16612926

申请日：2018-05-17

申请人： Genomic Health, Inc.

发明人： Margarita Lopatin ,  Athanasios Tsiatis ,  Christopher N. Silk ,  David P. Miller ,  Michael Crager ,  Phillip Febbo ,  Dejan Knezevic

IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12Q1/6886 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/154 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

摘要： The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.

公开(公告)号：US10260104B2

公开(公告)日：2019-04-16

申请号：US14887605

申请日：2015-10-20

申请人： GENOMIC HEALTH, INC.

发明人： Steven Shak ,  Frederick L. Baehner ,  Tara Maddala ,  Mark Lee ,  Robert J. Pelham ,  Wayne Cowens ,  Diana Cherbavaz ,  Michael C. Kiefer ,  Michael Crager ,  Audrey Goddard ,  Joffre B. Baker

IPC分类号： G06F19/00 ,  C12Q1/6886

摘要： The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.

公开(公告)号：US08725426B2

公开(公告)日：2014-05-13

申请号：US13752199

申请日：2013-01-28

申请人： Genomic Health, Inc.

发明人： Steve Shak ,  Mark Lee ,  William Novotny ,  Tara Maddala ,  Michael Crager ,  Diana Cherbavaz ,  Robert J. Pelham ,  Carl L. Millward ,  Dejan Knezevic

IPC分类号： G06F19/00 ,  C12Q1/68

CPC分类号： G06F19/20 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G06F19/00 ,  G16H50/30

摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.

摘要翻译： 本发明提供基于算法的分子测定法，其涉及从前列腺癌患者获得的生物样品中测量基因或其共表达基因的表达水平。 这些基因可以分组成功能性基因子集，用于计算可用于预测前列腺癌患者的临床结果的可能性的定量评分。

公开(公告)号：US20130196321A1

公开(公告)日：2013-08-01

申请号：US13752199

申请日：2013-01-28

申请人： GENOMIC HEALTH, INC.

发明人： Steve Shak ,  Mark Lee ,  William Novotny ,  Tara Maddala ,  Michael Crager ,  Diana Cherbavaz ,  Robert J. Pelham ,  Carl L. Millward ,  Dejan Knezevic

IPC分类号： G06F19/20 ,  C12Q1/68

CPC分类号： G06F19/20 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G06F19/00 ,  G16H50/30

摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.

摘要翻译： 本发明提供基于算法的分子测定法，其涉及从前列腺癌患者获得的生物样品中测量基因或其共表达基因的表达水平。 这些基因可以分组成功能性基因子集，用于计算可用于预测前列腺癌患者的临床结果的可能性的定量评分。